|
|
|
|
 |
|
ActiveSight to Provide Protein Crystallography to Serenex |
| Companies mentioned in this article: |
|
ActiveSight |
|
| 2/23/2005 @ 11:51 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
ActiveSight and Serenex, Inc. announced that they have entered into a broad agreement related to protein crystallography for drug discovery. The agreement covers the co-crystallization of Serenex proprietary molecules with proteins expressed by ActiveSight. Additional details of the agreement were not disclosed.
"We are excited to expand the scope of our productive relationship with Serenex," stated Ronald V. Swanson, Ph.D., Chief Scientific Officer for ActiveSight, "their proteomics-based discovery program makes them an excellent partner for our structural biology platform."
"This agreement will enable Serenex to understand on a molecular level how its compounds bind to their targets," said Dr. Gunnar Hanson, Director of Chemistry at Serenex. "We are very pleased to work with ActiveSight and have been impressed with their technical capability."
This marks the third announced collaboration for ActiveSight.
ABOUT ACTIVESIGHT
ActiveSight, a division of Rigaku/MSC, provides high-level structural biology services to advance clients' drug discovery efforts. ActiveSight features human target proteins available for rapid co-crystallization, including Hsp90 and fructose bisphosphatase. For more information visit www.active-sight.com
ABOUT SERENEX
Serenex is a chemoproteomics-based drug discovery company with a mission to develop proprietary human therapeutics that have improved likelihoods of clinical and economic success. Serenex's proprietary technologies enable the company to understand complex compound-target interactions and to discover novel compounds. To date, Serenex has lead compounds and pre-clinical programs in oncology and inflammation scheduled to enter clinical trials in early 2006. Serenex has worked with leading biotechnology and pharmaceutical companies improving their drug discovery programs in return for revenues and milestone payments. These companies include Chiron Corporation, Pfizer, Roche, Aventis and GlaxoSmithKline. For more information, visit Serenex's web site at www.serenex.com |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, August 28, 2008 |
 |
|
Orexigen Therapeutics to Present at Upcoming Investor Conferences Posted 3:16 PM PST
Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences Posted 3:15 PM PST
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference Posted 3:14 PM PST
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference Posted 3:13 PM PST
Volcano Presentation at Thomas Weisel Conference to Be Webcast Posted 3:12 PM PST
Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008 Posted 3:12 PM PST
Illumina to Present at Upcoming Investment Conferences in September Posted 7:43 AM PST
Optimer Pharmaceuticals to Present at BioCentury NewsMakers Conference Posted 7:42 AM PST
ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008 Posted 7:42 AM PST
|
| |
| Wednesday, August 27, 2008 |
|
|
Genoptix Announces Participation at the 2008 Southern California Investor Conference Posted 9:08 AM PST
|
| |
| Tuesday, August 26, 2008 |
|
|
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA Posted 3:42 PM PST
Cyntellect to Collaborate With the Burnham Institute for Medical Research; In situ live cell manipulation on LEAP to empower purification of stem cells and their differentiated progeny Posted 8:57 AM PST
TorreyPines Therapeutics Receives NASDAQ Deficiency Notice Posted 8:50 AM PST
JMAR Technologies Awarded Development Contract by the Johns Hopkins University Applied Physics Laboratory Posted 8:29 AM PST
Aperio Receives FDA Clearance for ER and PR Image Analysis Applications Posted 7:52 AM PST
|
| |
| Monday, August 25, 2008 |
|
|
Amylin and Lilly Set Date and Time for Conference Call; Companies Will Discuss Recent FDA Advisory Regarding BYETTA Posted 4:17 PM PST
Cripps Translational Science Institute Contributes to Discovery of Predisposition Gene for Childhood Cancer Posted 4:13 PM PST
Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference Posted 4:12 PM PST
Invitrogen Sets Date for Special Meeting of Shareholders to Vote on Proposed Merger with Applied Biosystems Posted 6:15 AM PST
|
| |
| Friday, August 22, 2008 |
|
|
ALISO VIEJO--- Valeant Pharmaceuticals to Present at UBS Global Life Sciences Conference Posted 6:20 AM PST
|
| |
| Thursday, August 21, 2008 |
|
|
Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 15 Years of 'Surfing For A Cure' on August 24 Posted 4:14 PM PST
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial Posted 4:13 PM PST
Patent Issued Related to Prometheus Proprietary Test Cbir1 Antigen Test Included in Diagnostic for Inflammatory Bowel Disease Posted 4:12 PM PST
Vaxfectin -formulated Measles DNA Vaccine Could Address Unmet Need for Infants Posted 4:11 PM PST
NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients Posted 4:03 PM PST
|
| |
| Tuesday, August 19, 2008 |
|
|
Karolinska Institute to Test Vical's Vaxfectin Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control Posted 7:59 AM PST
Invitrogen Launches Legionella Test to Streamline Surveillance Posted 7:29 AM PST
Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors Posted 7:26 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
